Lutetium-177 is linked to a molecule, often a peptide, that can bind to specific receptors on the surface of cancer cells. Once administered, the compound travels through the bloodstream and attaches to the cancer cells. The beta radiation emitted by Lu-177 then kills the cancer cells by causing DNA damage, while sparing most of the surrounding healthy tissue.
